| test (N=116) |
train (N=175) |
P-value | |
|---|---|---|---|
| Age (years) | |||
| Mean (SD) | 58.2 (8.61) | 56.9 (7.82) | 0.299 |
| Median [Min, Max] | 58.0 [40.0, 80.0] | 57.0 [38.0, 81.0] | |
| Mut_gene | |||
| BRCA1 | 89 (76.7%) | 128 (73.1%) | 0.583 |
| BRCA2 | 27 (23.3%) | 47 (26.9%) | |
| Stage | |||
| 1 | 0 (0%) | 1 (0.6%) | 0.61 |
| 2 | 1 (0.9%) | 4 (2.3%) | |
| 3 | 60 (51.7%) | 83 (47.4%) | |
| 4 | 55 (47.4%) | 87 (49.7%) | |
| R0 | |||
| R0 | 107 (92.2%) | 162 (92.6%) | 0.35 |
| R1 | 5 (4.3%) | 10 (5.7%) | |
| R2 | 1 (0.9%) | 0 (0%) | |
| R3 | 1 (0.9%) | 0 (0%) | |
| Missing | 2 (1.7%) | 3 (1.7%) | |
| Neoadjuvant_chemotherapy | |||
| 0 | 68 (58.6%) | 109 (62.3%) | 0.614 |
| 1 | 48 (41.4%) | 66 (37.7%) | |
| Chemotherapy_regimen | |||
| TC/AC | 109 (94.0%) | 165 (94.3%) | 1 |
| Other | 7 (6.0%) | 10 (5.7%) | |
| Chemotherapy_cycle_group | |||
| <6 | 8 (6.9%) | 14 (8.0%) | 0.634 |
| 6~8 | 106 (91.4%) | 155 (88.6%) | |
| >8 | 2 (1.7%) | 6 (3.4%) | |
| Pathological.type | |||
| EMCA | 3 (2.6%) | 4 (2.3%) | 0.941 |
| HGSC | 111 (95.7%) | 170 (97.1%) | |
| OCCC | 1 (0.9%) | 1 (0.6%) | |
| Missing | 1 (0.9%) | 0 (0%) |